EGFR and non-small cell lung carcinoma: A multicenter phase II clinical trial from the Korean Cancer Research Group (LU17–19) aimed to evaluate the efficacy of osimertinib in NSCLC patients with EGFR ex20ins mutations after standard chemotherapy failed.